Compare · DVA vs LSTA
DVA vs LSTA
Side-by-side comparison of DaVita Inc. (DVA) and Lisata Therapeutics Inc. (LSTA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. DVA focuses on Misc Health and Biotechnology Services, while LSTA focuses on Biotechnology: Pharmaceutical Preparations.
- DVA is the larger of the two at $10.88B, about 968.4x LSTA ($11.2M).
- DVA has been more active in the news (16 items in the past 4 weeks vs 8 for LSTA).
- DVA has more recent analyst coverage (14 ratings vs 0 for LSTA).
- Company
- DaVita Inc.
- Lisata Therapeutics Inc.
- Price
- -
- -
- Market cap
- $10.88B
- $11.2M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Misc Health and Biotechnology Services
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 16
- 8
- Recent ratings
- 14
- 0
DaVita Inc.
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company provides disease management services; vascular access services; clinical research programs; physician services; and comprehensive care services. As of December 31, 2020, it provided dialysis and administrative services in the United States through a network of 2,816 outpatient dialysis centers serving approximately 204,200 patients; and operated 321 outpatient dialysis centers located in 10 countries outside of the United States serving approximately 36,700 patients. Further, the company provides acute inpatient dialysis services in approximately 900 hospitals and related laboratory services in the United States. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.
Latest DVA
- Director Barbara J Desoer was granted 286 shares (SEC Form 4)
- Director Pamela M Arway was granted 286 shares, increasing direct ownership by 1% to 27,509 units (SEC Form 4)
- Director Gregory J. Moore was granted 286 shares, increasing direct ownership by 4% to 8,377 units (SEC Form 4)
- Director Adam H Schechter was granted 286 shares, increasing direct ownership by 5% to 6,256 units (SEC Form 4)
- Director Jason M. Hollar was granted 286 shares, increasing direct ownership by 4% to 7,169 units (SEC Form 4)
- Director Dennis W Pullin was granted 286 shares, increasing direct ownership by 10% to 3,235 units (SEC Form 4)
- Chief Executive Officer Javier Rodriguez covered exercise/tax liability with 5,165 shares, decreasing direct ownership by 0.61% to 835,243 units (SEC Form 4) to cover taxes
- Director Wendy Lee Schoppert was granted 286 shares (SEC Form 4)
- Director Phyllis R Yale was granted 286 shares, increasing direct ownership by 3% to 10,089 units (SEC Form 4)
- Chief Accounting Officer Christopher Michael Berry covered exercise/tax liability with 1,031 shares, decreasing direct ownership by 5% to 18,609 units (SEC Form 4) to satisfy withholding tax
Latest LSTA
- SEC Form 10-Q filed by Lisata Therapeutics Inc.
- SEC Form S-3 filed by Lisata Therapeutics Inc.
- SEC Form S-8 filed by Lisata Therapeutics Inc.
- Amendment: Lisata Therapeutics Inc. filed SEC Form 8-K: Financial Statements and Exhibits
- SEC Form DEFA14A filed by Lisata Therapeutics Inc.
- Lisata Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits
- Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces MAR001 Reduces Triglycerides Without Worsening Glycemic Control in Phase 2b TYDAL-TIMI 78 Trial; Results Presented as AHA 2026 Late-Breaker and Published in The New England Journal of Medicine
- Marea Therapeutics, a Subsidiary of Lisata Therapeutics, to Participate in Upcoming November Investor Conferences
- SEC Form DEF 14A filed by Lisata Therapeutics Inc.
- SEC Form 3 filed by Lisata Therapeutics Inc.